• Acumen Pharmaceuticals announced today that its Phase 2 ALTITUDE-AD trial of sabirnetug for early Alzheimer’s disease failed its primary endpoint.
• Neither dose showed meaningful improvement in cognitive or functional decline compared with placebo; key secondary efficacy endpoints also failed.
• Development of sabirnetug will cease, including the trial’s open-label extension.
• Cash conservation measures are planned while strategic options are evaluated, including for the Enhanced Brain Delivery program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610300700PRIMZONEFULLFEED9856668) on October 30, 2026, and is solely responsible for the information contained therein.